Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingPhase 3interventionalRules rewrite

Phase 3: testing [Phase 1] Clozapine for Treatment-resistant Schizophrenia

The goal of this study is to optimize treatment strategies for Chinese patients with treatment-resistant schizophrenia (TRS). It will compare two types of treatment: 1.

Official registry: https://clinicaltrials.gov/study/NCT07918222 · Shanghai Mental Health Center · enrollment listed as 300

What this phase means

Phase 3: this treatment already looked useful in smaller studies. Now it is tested in a large group, often against standard care or a dummy treatment, to see if it should be approved.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are [Phase 1] Clozapine, [Phase 1] Aripiprazole, or [Phase 1] Amisulpride. The registry lists allocation as randomized. The goal of this study is to optimize treatment strategies for Chinese patients with treatment-resistant schizophrenia (TRS).

They plan to enroll about 300 people at Shanghai. Taking part typically means taking a study drug (or dummy pill), using or being fitted with a device plus check-ins.

Official title (unrewritten)

Sequential Treatment Approaches for Treatment-Resistant Schizophrenia (STATRS): A Randomized Controlled Trial of Pharmacological Optimization and Neuromodulation in Chinese Patients

Interventions: [Phase 1] Clozapine, [Phase 1] Aripiprazole, [Phase 1] Amisulpride, [Phase 2] Modified Electroconvulsive Therapy (MECT), [Phase 2] Magnetic Seizure Therapy (MST)

Primary outcome (registry wording): PANSS reduction rate at Week 8 during the pharmacological optimization phase

Who it is for (from inclusion criteria)

  • Ages 18 Years to 55 Years
  • General who can join applicable to all participants:
  • Participants must meet DSM-5 diagnostic criteria for schizophrenia
  • Eligibility for the pharmacological optimization phase:
  • Participants eligible for the pharmacological optimization phase must meet the general TRS criteria above and must be clozapine-who have not tried this kind of treatment before
  • Eligibility for the neuromodulation phase:
  • Participants eligible for the neuromodulation phase must meet the TRS criteria described above
  • Participants may enter the neuromodulation phase through either of the following pathways:

Public study contact (from the registry)

DengTang Liu, MD, PhD

+86-18017311138

erliu110@126.com

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Related recruiting trials in this snapshot

RecruitingPhase 1 / Phase 2Houston, Texas
Phase 1 / Phase 2: testing Ocrelizumab infusion for Schizo-Affective Type of Psychosis

Some people who have what doctors currently call schizophrenia or bipolar disease may actually have a brain disease caused by auto-antibodies. Auto-antibodies are produced when the normal defense mechanism of the body goes wrong and begins to attack the body, similar to "friendly fire." Auto-antibodies attack brain receptors and then the person who has this problem begins to have hallucinations and other manifestations of schizophrenia, like feeling that people can see what they are thinking and also feeling that other people do not like them.

NCT03971487 · Official ClinicalTrials.gov record · The Methodist Hospital Research Institute

FAQ about this NCT record

Is NCT07918222 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07918222?

Phase 3. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07918222?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary